




# Evaluation of Antimalarial Activity of 80% Methanolic Root Extract of *Dorstenia barnimiana* Against *Plasmodium berghei*-Infected Mice

Dagninet Derebe <sup>1</sup>  
Muluken Wubetu <sup>2</sup>  
Amare Alamirew <sup>3</sup>

<sup>1</sup>Department of Pharmacy, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia;

<sup>2</sup>Department of Pharmacy, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia;

<sup>3</sup>Department of Community Health, ALKAN Health Science, Business and Technology College, Bahir Dar, Ethiopia

**Background:** Due to resistance of parasites, costs, and safety issues with currently available drugs, there is a need to discover new antimalarials. Medicinal plants are one of the most important sources of new drugs. The purpose of this study was to evaluate the antimalarial activity of a methanolic root extract of *Dorstenia barnimiana* in Swiss albino mice infected with *Plasmodium berghei*.

**Methods:** Four-day suppressive, curative, and prophylactic tests were performed on mice infected with *P. berghei* to evaluate the antimalarial activity of a methanolic root extract of the plant. Parasitemia suppression, survival time, body-weight change, rectal temperature change, and packed-cell volume were used to evaluate the activity of the extract. Data were analyzed using one-way ANOVA followed by Tukey's post hoc test for comparisons between and within groups, with  $P < 0.05$  considered statistically significant.

**Results:** The *D. barnimiana* root extract showed significant ( $P < 0.01$ ) parasitemia-suppressive activities in all models compared to the negative control. The extract increased mean survival time and prevented weight loss, reduction in temperature, and anemia significantly in all tested doses in 4-day suppressive and curative tests.

**Conclusion:** Based on these findings, *D. barnimiana* root has promising antimalarial activity and can be considered a potential source to develop new agents.

**Keywords:** antimalarial, *Dorstenia barnimiana*, *Plasmodium berghei*, 4-day suppressive test, curative test, prophylactic test

## Background

Malaria is still a major public-health problem and is one of the major obstacles to the socioeconomic development of several developing countries.<sup>1,2</sup> According to the 2020 World Malaria Report, in 2019 alone, malaria caused - 229 million morbidities and 409,000 deaths globally. A majority of the deaths and morbidities were in Africa. In 2019, 94% of malaria morbidity and 94% of malaria mortality was in Africa. Children aged <5 years are the most affected age-group, accounting for 67% of all mortality due to malaria globally in 2019 alone.<sup>3</sup>

In Ethiopia, like other African countries, malaria is one of the leading causes of morbidity and mortality. Nearly 80% of districts in Ethiopia are considered “malarious,” and around 68% of the population are at risk of malaria. As a result of the unstable transmission of malaria in Ethiopia throughout the year, protective immunity among populations is relatively low. Among the *Plasmodium* spp.,

Correspondence: Dagninet Derebe  
Email [dagninet37@yahoo.com](mailto:dagninet37@yahoo.com)

*P. falciparum* is the major cause of malaria in Ethiopia, responsible for 65%–75% of cases, with *P. vivax* responsible for 25%–35%. *P. ovale* and *P. malariae* are rare.<sup>4–8</sup>

Due to the unavailability of an effective vaccine, chemotherapy and vector control comprise the core approach to combat the devastating effect of malaria.<sup>9</sup> However, this modality of management is still confronted by numerous challenges, including the alarming spread of insecticide-resistant female anophelid mosquitoes, chemotherapy-resistant *Plasmodium* spp. in many parts of the world, and a limited number of effective antimalarial drugs.<sup>10–14</sup> Therefore, new knowledge, products, and measures, and in particular new antimalarial drugs, are urgently needed to confront the devastating effect of malaria.

Traditionally used medicinal plants are a relevant source of new therapeutic approaches. According to the World Health Organization, approximately 80% of African and Asian populations depend on traditional medicine for their primary health-care needs. In Ethiopia, >80% of the population depends on traditional medicine, mainly medicinal plants, to treat a variety of diseases, including malaria, to meet their primary health-care needs. This is due to the cultural acceptability of healers, the relatively low cost, and difficulty in accessing modern medicine.<sup>15,16</sup> Medicinal plants are the chief source of drugs for medicine. Approximately 25% of currently prescribed drugs are obtained from plants, and >11% of essential drugs are obtained from plants or synthetic drugs obtained from natural precursors.<sup>17</sup>

Globally, >1,000 plant species have been reported to be used for the treatment of malaria traditionally, and thus are potential sources of new antimalarial drugs.<sup>18</sup> The root of *Dorstenia barnimiana*, known locally as “*werk bemieda*”, is an erect perennial herb, and one of the most frequently used plants for medicinal purposes. It has been used by the local community as a traditional remedy against acute coughing (tuberculosis), leprosy, stomach illness, fungal disease, diarrhea, fever, headache, malaria, and the common cold and as an insect repellent.<sup>19–24</sup> Specifically for malaria, the root powder is mixed with aguat in local name and fresh filtrate taken on an empty stomach once every other day for 3 days. However, there is no literature that gives scientific validation of the antimalarial activity of the root of this plant. This study was done to evaluate the antimalarial activity of the plant scientifically.

## Methods

### Plant Collection and Preparation of Plant Materials

The roots of *D. barnimiana* were collected in January 2018 from around Bahir Dar. Bahir Dar is located at the exit of Abbay from Lake Tana at an altitude of 1820 m above sea level. The city is located approximately 578 km northwest of Addis Ababa. Bahir Dar has a borderline-tropical savanna climate. Afternoon temperatures are very warm to hot year-round and morning temperatures cool; however, the diurnal range is much larger in the largely cloudless dry season. The plant was authenticated by the National Herbarium of Addis Ababa University, with voucher identity of DD003/2018 given and deposited. The fresh roots were thoroughly washed with water to and then dried under shade with optimal ventilation. After being chopped, roots were powdered using electronic crushers. The powder was kept in a well-closed amber-colored bottle at room temperature until extracted.

### Preparation of Plant Extracts

Weighed using a sensitive digital balance, 100 g dried-root powder was mixed with 80% methanol in an Erlenmeyer flask at room temperature. Then, the plant and solvent mixtures were extracted by cold maceration by placing them on an orbital shaker for 3 days at 160 rpm. On the third day, the extract was separated from the marc by filtration using Whatman filter paper number 1 with pore size 0.7 μm. This procedure was done three times for exclusive extraction. Then, the extract was dried by removing the methanol under reduced pressure using a rotary evaporator at 45 rpm and 40°C. The extract was further concentrated with lyophilizer (Wagtech Jouan Nordic DK-3450) at –40°C under vacuum pressure. Finally, the percentage yield of the extract was calculated by weighing the dry extract, and all the dry extracts were stored in airtight plastic containers and maintained in a refrigerator at –20°C until use.

### Reagents and Drugs

Chloroquine phosphate, distilled water, Giemsa stain, trisodium citrate, absolute methanol, and other chemicals for phytochemical screening, such as 20% NaOH, chloroform, sulfuric acid, 95% ethanol, ferric chloride, glacial acetic acid, acetic acid HCl, 10% ammonia, and Mayer’s reagent

were used in this experiment. Most these were obtained from the Pharmacy Department of Bahir Dar University, and the rest purchased from the Ethiopian Pharmaceutical Supply Agency or certified suppliers.

## Experimental Animals

For this experiment, 95 Swiss albino mice of both sexes aged 4–6 weeks and weighing 22–28 g were used. They were bred in the animal house of the Pharmacy Department and kept in regular plastic cages with wood-chip bedding at a controlled room temperature of (21°C ±2°C), with a 12/12-hour light/dark cycle and relative humidity of 40%–50%. They were fed pellets and drinking water ad libitum. Care and handling of the animals were in accordance with the guidelines of the Organization for Economic Cooperation and Development (OECD) and the Institute for Laboratory Animal Research. Acclimatization to a working environment was done a week before commencing the experiment.<sup>25,26</sup>

## Parasite

The chloroquine-sensitive *Plasmodium berghei* ANKA strain, the parasite used to infect mice in all models, was purchased from the Aklilu Lemma Institute of Pathobiology. Serial blood passage from infected mouse to naïve mouse weekly was done to maintain the *P. berghei* in our laboratory. Donor mice with a parasitemia level of 20%–30% were killed and infected blood collected by cardiac puncture into heparinized vacutainer tubes containing 0.5% trisodium citrate. The blood was then diluted in normal saline based on the parasitemia level of the donor mouse and 0.2mL infected blood containing about 10<sup>7</sup> *P. berghei* (quantified with thick blood film) parasitized red blood cells (RBCs) transferred to uninfected mice intraperitoneally (IP). Each mouse used in the study was infected in the same way.<sup>27</sup>

## Preliminary Phytochemical Screening

The presence or absence of alkaloids, flavonoids, terpenoids, phenols, saponins, tannins, cardiac glycosides, phytoosterol, and resins was tested in the methanolic root extract of *D. barnimiana* based on established standards<sup>28,29</sup> to relate the secondary metabolites to their antimalarial activity.

## Acute Oral Toxicity Test

Acute oral toxicity of the extract was assessed in young, nulliparous, and nonpregnant Swiss albino mice based on

the limit-test advice of OECD guideline 425.<sup>25</sup> After acclimatizing for 1 week, one mouse was fasted for 4 hours, received a single oral dose of 2,000 mg/kg extract, then fasted again for the next 2 hours. The mouse was observed closely for the first 30 minutes after dosing and regularly for the next 24 hours, then daily for 14 days for any physical or behavioral abnormality. Based on the results from the first mouse, an additional four mice were fasted overnight, administered a single dose of 2,000 mg/kg, and followed similarly.

## Grouping and Dosing of Animals

Thirty *P. berghei*-infected mice were randomly divided into five groups (n=6) in each model to evaluate the antimalarial activity of the extract. Group 1 was used as a negative control and received 10 mL/kg (0.2–0.3 mL) distilled water, groups 2–4 received extracts of *D. barnimiana* 100 mg/kg (DB100), DB200, and DB400, respectively, and group 5 was used as positive control, receiving chloroquine 25 mg/kg (CQ25). All treatments were given by oral gavage.

## In Vivo Antimalarial Screening Four-Day Suppressive Test

This test followed a standard protocol.<sup>30,31</sup> Three hours after *P. berghei* infection, treatment commenced on the first day and continued for the next 3 days once daily (D0–D3). Parasitemia level and percentage parasitemia suppression were determined by taking blood from the tail of each mouse on the fifth day (D4).<sup>27</sup> Each mouse was also observed for 28 days after treatment to determine mean survival time. Weight, temperature, and packed-cell volume (PCV) were determined just before infection and on the fifth day (D4).

## Curative Test

This test was done using the method described by Ryley and Peters.<sup>32</sup> Thirty adult Swiss albino mice of both sexes were infected with *P. berghei* on the first day (D0). Treatment was commenced after 72 hours' (D3) infection with *P. berghei*, then given once daily from day 3 (D3) to day 6 (D6). Parasitemia levels and percentage parasitemia suppression were determined by taking blood from the tail of each mouse on the seventh day. Each mouse was observed till 28 days postinfection to determine mean survival time. Rectal temperature, body weight, and PCV were measured on day 3 (before treatment) and day 7 (after treatment).

## Prophylactic Test

Evaluation of the prophylactic potential of the extract was done as per prior methods.<sup>33</sup> Thirty Swiss albino mice were treated daily for four (D0–D3) consecutive days. Each mouse was infected with *P. berghei* IP on the fifth day (D4). Parasitemia levels and percentage parasitemia suppression were determined by taking blood from the tail of each mouse 72 hours after infection (on the seventh day). Each mouse was also observed till 28 days from the initiation of treatment to determine mean survival time. Rectal temperature, body weight, and PCV were measured on day one (before treatment) and on day seven (last day of follow-up).

## Determination of Parasitemia Levels and Parasitemia Suppression

Thick and thin smears of blood were taken from the tail of each mouse. The smears were placed on microscope slides, fixed with absolute methanol for 30 seconds, and stained with 10% Giemsa stain at pH 7.2 for 15 minutes. The slides were taken out, washed gently with tap water, and dried at room temperature. The slides were examined under light microscopy to determine the percentage of parasitized RBCs. For each mouse, two stained slides were used, five fields on each slide examined, and the average taken.<sup>34</sup> Average percentage parasitemia and percentage parasitemia suppression was calculated using the following formula, and extracts that had parasitemia suppression  $\geq 30\%$  were considered active.<sup>5,35</sup>

$$\% \text{ Parasitemia} = \frac{\text{Number of parasitized RBC}}{\text{Total number of RBC count}} \times 100$$

$$\% \text{ Suppression} = \frac{\text{Parasitemia in negative control} - \text{Parasitemia in treated group}}{\text{Parasitemia in the negative control}} \times 100$$

## Determination of Mean Survival Time

Mean survival time was determined by observing the mice for 28 days after infection with *P. berghei*. The average value was computed versus the negative control. Deaths that occurred before day 5 were considered due to toxicity. The mean survival time of each group was calculated:<sup>35</sup>

$$\text{Mean survival time} = \frac{\text{Sum of survival time of all mice in a group (days)}}{\text{Total number of mice in that group}}$$

## Determination of Packed-Cell Volume

PCV is another important parameter to evaluate the anti-malarial activity of extracts. Heparinized microhematocrit capillary tubes were used to take blood from the tail of each mouse. The tubes were centrifuged at 12,000 rpm for 5 minutes in a microhematocrit centrifuge after sealing. PCV was measured using the Wintrobe method.<sup>35,36</sup>

$$PCV = \frac{\text{Volume of erythrocytes in a given volume of blood}}{\text{Total blood volume}} \times 100\%$$

## Ethics

Handling of the animals was in accordance with the international guidelines for the use and maintenance of experimental animals.<sup>26</sup> The ethical clearance was requested and obtained (HRTT/10/311/2019) from the research and ethics review committee of the Amhara Public health Institute before commencing the actual work.

## Data Analysis

Means  $\pm$  SEM are used to express the data obtained. SPSS 20.0 was used for data analysis. To test for significance, inter- and intragroup ANOVA was performed, followed by Tukey's HSD post hoc test.  $P < 0.05$  was considered statistically significant.

## Results

### Preliminary Phytochemical Screening

Alkaloids, flavonoids, phenols, saponins, tannins, and cardiac glycosides were detected on phytochemical screening, whereas terpenoids, phytosterol, resins were not. The yield of the root of *D. barnimiana* extract was 44.3% (w:w).

### Acute Toxicity Study

Mortality was not observed at 2,000 mg/kg during observation, meaning the LD<sub>50</sub> of the extract was  $> 2,000$  mg/kg. The mice did not show any physical or behavioral abnormalities, eg, diarrhea, lacrimation, reduction in motor and feeding activities, hair erection, or any other central nervous system disturbances, during observation.

### Four-Day Suppressive Test

The extract suppressed parasitemia levels significantly ( $P < 0.001$ ) in a dose-dependent fashion compared with the negative control at all tested doses on the 4-day suppressive test. The extract had significant parasitemia-suppression effect at all tested doses, with the highest suppression

obtained at 400 mg/kg (54.87%), as shown in Table 1. However, the effect was lower compared to the standard drug — chloroquine (100%).

The extract had significant ( $P<0.05$  for lowest,  $P<0.001$  for middle and highest doses) effects on survival time compared with the negative control. However, the survival effect was very low compared to chloroquine (Table 2).

**Table 1** Phytochemicals in *Dorstenia barnimiana*

Secondary metabolites	Reagent	Result
Alkaloids	Mayer's test	+
Flavonoids	Lead acetate Test	+
Phenols	Ferric chloride test	+
Saponins	Foam test	+
Tannins	Gelatin Test	+
Cardiac glycosides	Keller Killian's test	+
Terpenoids	Copper acetate test	–
Phytosterol	Salkowski's test	–
Resins	Precipitation test	–

**Notes:** +, present; –, absent.

**Table 2** Parasitemia-Suppressive and Mean Survival-Time Effects of *Dorstenia barnimiana* Root Extract Against *Plasmodium berghei* on 4-day Suppressive Test

	% Parasitemia	% Suppression	Survival Time (days)
NC	39.44±1.37	0	6.50±1.87
DB100	25.32±3.17	35.78 <sup>a3b3d1e3</sup>	8.50±1.05 <sup>a1b3d3e3</sup>
DB200	21.95±1.29	44.35 <sup>a3b3c1e2</sup>	11.83±1.47 <sup>a3b3c3e3</sup>
DB400	17.80±1.33	54.87 <sup>a3b3c3d2</sup>	15.50±1.87 <sup>a3b3c3d3</sup>
CQ25	0	100 <sup>a3c3d3e3</sup>	28±0 <sup>a3c3d3e3</sup>

**Notes:** Data expressed as means ± SEM (n=6). <sup>a</sup>Compared to NC, <sup>b</sup>chloroquine 25 mg/kg, <sup>c</sup>100 mg/kg, <sup>d</sup>200 mg/kg, and <sup>e</sup>400 mg/kg extract. <sup>1</sup> $P<0.05$ ; <sup>2</sup> $P<0.01$ ; <sup>3</sup> $P<0.001$ .

**Abbreviations:** NC, negative control; DB100, *Dorstenia barnimiana* root extract 100 mg/kg; CQ25, chloroquine 25 mg/kg.

**Table 3** Body-weight and Rectal Temperature Effects of *Dorstenia barnimiana* Root Extract Against *Plasmodium berghei* on 4-Day Suppressive Test

	Weight (g)		%Change	Temperature (°C)		%Change
	D0	D4		D0	D4	
NC	24.83±2.04	20.95±2.42	–15.62	36.02±0.45	34.10±0.52	–5.33
DB100	25.50±1.87	23.33±1.75	–8.51 <sup>a1b1</sup>	36.10±0.59	34.85±0.28	–3.46 <sup>a2b3d1e3</sup>
DB200	25.82±1.47	24.33±1.21	–5.80 <sup>a2</sup>	36.23±0.33	35.36±0.41	–2.40 <sup>a3b3c1e1</sup>
DB400	25.33±2.16	25.17±1.72	–0.63 <sup>a3</sup>	36.32±0.48	35.93±0.42	–1.07 <sup>a3b2c3d1</sup>
CQ25	25.30±1.80	26.00±1.79	2.76 <sup>a3c1</sup>	36.43±0.33	36.67±0.12	0.66 <sup>a3c3d3e2</sup>

**Notes:** Data expressed as means ± SEM (n=6). <sup>a</sup>Compared to NC, <sup>b</sup>chloroquine 25 mg/kg, <sup>c</sup>100 mg/kg, <sup>d</sup>200 mg/kg, and <sup>e</sup>400 mg/kg extract. <sup>1</sup> $P<0.05$ ; <sup>2</sup> $P<0.01$ ; <sup>3</sup> $P<0.001$ .

**Abbreviations:** NC, negative control; DB100, *Dorstenia barnimiana* root extract 100 mg/kg; CQ25, chloroquine 25 mg/kg.

## Effect on Body Weight and Rectal Temperature in 4-Day Suppressive Test

The extract prevented weight loss and decrease in rectal temperature associated with infection in a dose-dependent fashion ( $P<0.05$ ) at all tested doses compared to the negative control (Table 3). However, the effect of the extract was significantly lower than the positive control.

## Effect on Packed-Cell Volume in Suppressive Test

The extract also showed a significant ( $P<0.001$ ) effect on prevention of PCV reduction associated with infection at all tested doses compared to the negative control. The effect on PCV was dose-dependent: highest at 400 mg/kg and lowest at 100 mg/kg at the end of treatment (Figure 1).


## Curative Test

The curative effect of the extract was found to be statistically significant at all tested doses compared to the negative control (Table 4). The effect of parasitemia suppression was dose-dependent, with the highest effect at 400 mg/kg (58.28%), followed by 200 mg/kg (47.71%) and 100 mg/kg (35.65%). The extract also increased survival time significantly at all tested doses compared to the negative control. However, parasitemia-suppressive and survival effects in extract-treated groups were significantly lower than with standard drugs.

## Effect of Extract on Body Weight and Rectal Temperature in Curative Test

Prevention of body-weight reduction in infected mice at all tested extract doses was statistically significant compared to the negative control (Table 5). However, there was no statistically significant difference between doses. The





**Figure 1** Packed cell-volume change in malaria-infected mice treated with extract on the 4-day suppression test compared with negative- and positive-control groups. **Abbreviations:** NC, negative control; DB100, *Dorstenia barnimiana* root extract 100 mg/kg; CQ25, chloroquine 25 mg/kg.

extract also significantly prevented reduction in rectal temperature associated with infection at all tested doses compared to the negative control.

**Table 4** Parasitemia-Suppressive and Mean Survival-Time Effects of *Dorstenia barnimiana* Root Extract Against *Plasmodium berghei* on Curative Test

	% Parasitemia	% Suppression	Survival Time (days)
NC	48.25±2.00	0	6.83±0.75
DB100	31.05±2.02	35.65 <sup>a3b3d3e3</sup>	9.50±1.05 <sup>a2b3d3e3</sup>
DB200	26.27±1.13	47.71 <sup>a3b3c3e3</sup>	13.17±1.47 <sup>a3b3c3e1</sup>
DB400	20.13±2.11	58.28 <sup>a3b3c3d3</sup>	15.50±1.87 <sup>a3b3c3d1</sup>
CQ25	0	100 <sup>a3c3d3e3</sup>	28±0 <sup>a3c3d3e3</sup>

**Notes:** Data expressed as means ± SEM (n=6). <sup>a</sup>Compared to NC, <sup>b</sup>chloroquine 25 mg/kg, <sup>c</sup>100 mg/kg, <sup>d</sup>200 mg/kg, and <sup>e</sup>400 mg/kg extract. <sup>1</sup>P<0.05; <sup>2</sup>P<0.01; <sup>3</sup>P<0.001.

**Abbreviations:** NC, negative control; DB100, *Dorstenia barnimiana* root extract 100 mg/kg; CQ25, chloroquine 25 mg/kg.

### Effect of Extract on Packed-Cell Volume in Curative Test

PCV reduction associated with infection was significantly (P<0.05) prevented at all tested doses compared to the negative control. The effect on PCV was dose-dependent: highest at 400 mg/kg and lowest at 100 mg/kg at the end of treatment (Figure 2).

### Prophylactic Test


All tested doses of the extract significantly (P<0.001) reduced the average parasite load compared to the negative control in a dose-dependent manner. Maximum parasitemia suppression was observed at the highest tested dose of 400 mg (58.15%), followed by 200 mg (48.32%) and 100 mg (33.86%). Survival time of the infected mice pretreated with the extract indicated that only the middle and highest doses were capable of significantly (P<0.001) prolonging survival time compared to controls. The lowest

**Table 5** Body-weight and Rectal Temperature Effects of *Dorstenia barnimiana* Root Extract Against *Plasmodium berghei* on Curative Test

	Weight (g)		%Change	Temperature (°C)		%Change
	D3	D7		D3	D7	
NC	26.58±1.14	21.78±1.30	-18.06	36.48±0.65	34.15±0.26	-6.39
DB100	27.23±0.74	25.15±0.92	-7.64 <sup>a3b3</sup>	36.58±0.18	34.90±0.48	-4.59 <sup>a1b3e3</sup>
DB200	26.85±1.01	25.68±0.99	-4.36 <sup>a3b3</sup>	36.52±0.64	35.58±0.58	-2.12 <sup>a3b3</sup>
DB400	26.62±0.91	26.40±0.72	-0.83 <sup>a3b2</sup>	36.57±0.36	36.17±0.38	-0.41 <sup>a3b1c3</sup>
CQ25	27.23±0.53	28.83±0.77	5.88 <sup>a3</sup>	36.30±0.18	36.97±0.41	1.85 <sup>a3</sup>

**Notes:** Data expressed as means ± SEM (n=6). <sup>a</sup>Compared to NC, <sup>b</sup>chloroquine 25 mg/kg, <sup>c</sup>100 mg/kg, and <sup>d</sup>400 mg/kg extract. <sup>1</sup>P<0.05; <sup>2</sup>P<0.01; <sup>3</sup>P<0.001.

**Abbreviations:** NC, negative control; DB100, *Dorstenia barnimiana* root extract 100 mg/kg; CQ25, chloroquine 25 mg/kg.



**Figure 2** Packed cell-volume change in malaria-infected mice treated with extract on the curative test compared with negative- and positive-control groups. **Abbreviations:** NC, negative control; DB100, *Dorstenia barnimiana* root extract 100 mg/kg; CQ25, chloroquine 25 mg/kg.

dose (100 mg/kg) did not increase survival time significantly compared to the negative control (Table 6).

### Effect of Extract on Body Weight and Rectal Temperature in Prophylactic Test

Only the highest dose of extract showed a significant protective effect for body-weight reduction compared to

the negative control. However, the middle and highest doses significantly prevented rectal temperature reduction compared to the negative control (Table 7).

### Effect of Extract on Packed-Cell Volume in Prophylactic Test

Unlike the standard drug, the extract did not have a significant effect on PCV reduction associated with infection at any tested dose compared to the negative control (Figure 3).

**Table 6** Parasitemia-Suppressive and Mean Survival-Time Effects of *Dorstenia barnimiana* Root Extract Against *Plasmodium berghei* on Prophylactic Test

	% Parasitemia	% Suppression	Survival Time (days)
NC	30.42±2.38	0	6.67±1.21
DB100	20.12±2.08	33.86 <sup>a3b3d2e3</sup>	8.50±1.05 <sup>b3e3</sup>
DB200	15.72±1.29	48.32 <sup>a3b3c2e1</sup>	10.17±1.17 <sup>a3b3e1</sup>
DB400	12.73±0.97	58.15 <sup>a3b3c3d1</sup>	12.33±1.97 <sup>a3b3c3d1</sup>
CQ25	0	100 <sup>a3</sup>	28±0 <sup>a3</sup>

**Notes:** Data expressed as means ± SEM (n=6). <sup>a</sup>Compared to NC, <sup>b</sup>chloroquine 25 mg/kg, <sup>c</sup>100 mg/kg, <sup>d</sup>200 mg/kg, and <sup>e</sup>400 mg/kg extract. <sup>1</sup>P<0.05; <sup>2</sup>P<0.01; <sup>3</sup>P<0.001. **Abbreviations:** NC, negative control; DB100, *Dorstenia barnimiana* root extract 100 mg/kg; CQ25, chloroquine 25 mg/kg.


## Discussion

The root extract was found to be significantly effective in reducing parasitemia loads at all tested doses in all three models. The difference in parasitemia-suppressive activity of the extract among the doses was also statistically significant, indicating it was dose-dependent. Based on in vivo antimalarial activity classification, the root extract of the plant had moderate antimalarial activity in all three models.<sup>37</sup> The parasitemia-suppressive effect of the plant was similar to other plant extracts used for malaria, such

**Table 7** Body-Weight and Rectal Temperature Effects of *Dorstenia barnimiana* Root Extract Against *Plasmodium berghei* on Prophylactic Test

	Weight (g)		%Change	Temperature (°C)		%Change
	D0	D7		D0	D7	
NC	26.98±0.98	24.17±1.46	-10.42	36.23±0.54	33.72±1.09	-6.93
DB100	26.33±1.36	24.95±1.98	-5.24	36.22±0.20	34.55±0.36	-4.61
DB200	26.28±0.95	25.37±0.53	-3.46	36.25±0.29	35.06±0.45	-3.28 <sup>a2</sup>
DB400	26.98±1.11	26.52±0.76	-1.7 <sup>a1</sup>	36.37±0.46	35.92±0.69	-1.24 <sup>a3c2</sup>
CQ25	26.37±1.09	26.15±0.92	-0.83 <sup>a2</sup>	36.38±0.27	36.32±0.29	-0.16 <sup>a3c2</sup>

**Notes:** Data expressed as means ± SEM (n=6). <sup>a</sup>Compared to NC, and <sup>1</sup>100 mg/kg extract. <sup>1</sup>P<0.05; <sup>2</sup>P<0.01; <sup>3</sup>P<0.001. **Abbreviations:** NC, negative control; DB100, *Dorstenia barnimiana* root extract 100 mg/kg; CQ25, chloroquine 25 mg/kg.



**Figure 3** Packed cell-volume change in malaria-infected mice treated with extract on the prophylactic test compared with negative- and positive-control groups. **Abbreviations:** NC, negative control; DB100, *Dorstenia barnimiana* root extract 100 mg/kg; CQ25, chloroquine 25 mg/kg.

as *Calpurnia aurea*,<sup>10</sup> *Combretum molle*,<sup>38</sup> *Echinops kebericho*,<sup>39</sup> and *Brassica nigra*.<sup>40</sup> Also, the extract was atoxic up to a dose of 2,000 mg/kg, which agrees with the WHO classification of hazardous substances.<sup>41</sup> However, at all tested doses, this plant had significantly lower parasitemia-suppression activity than the positive control. This may have been due to the low level of active compound(s) in the extract.

Mean survival time was also used to evaluate the anti-malarial activity of the extract in all three models. The extracts prolonged the survival of mice on the 4-day suppressive and curative tests at all tested doses in a dose-dependent manner, and at the middle and highest doses on the prophylactic test. The greatest effect on survival time was obtained with the dose achieving the highest parasitemia suppression, in agreement with other in vivo antimalarial studies.<sup>5,34,42,43</sup> This indicates that the significant effect on survival time may be due to the suppression of parasitemia and reduced the overall pathological effect of the parasite in the study mice.

As with human malarial infection, *Plasmodium*-infected animals showed decreased food consumption and body weight during the experiment.<sup>44</sup> As such, prevention of body-weight loss was used in this study to evaluate the antimalarial activity of plant extracts in all models. At all tested doses, the extract significantly prevented weight loss in a dose-dependent manner compared to the negative control on the 4-day suppression and curative tests, but not the prophylaxis test. This prevention of weight loss is in line with other similar studies.<sup>5,38,45,46</sup> This effect may have been because the extract significantly

suppressed parasitemia and thereby reduced anemia and the overall pathological effect of the parasite in the test groups and improved food consumption.

Additionally, in all tested models, the extract produced a significant effect on rectal temperature of the *Plasmodium*-infected mice at all tested doses, except at the lowest dose in the prophylactic model. This study was consistent with other in vivo antimalarial tests.<sup>47</sup> This effect can be attributed to the parasiticidal activity of the extract resulting in the prevention of alteration in body temperature occurring due to the parasite infection. The parasite infection reduce to rectal temperature due to reduction food intake, reduce catabolic state.

The other important parameter in antimalarial studies is PCV, which is a measure of the relative mass of cells present in a sample of blood.<sup>48</sup> The destruction of infected and uninfected RBCs, either by parasites or as a result of an immunoresponse to parasite infection or both, brings a reduction in PCV of RBCs in the blood,<sup>49</sup> resulting in anemia,<sup>50</sup> so any significant prevention of PCV loss by plant extracts can support their antiplasmodial activity. In this study, the extract was able to prevent the loss in PCV significantly compared to controls at all tested doses on the 4-day suppressive and curative tests, but not the prophylaxis one. Such prevention of PCV loss by plant extracts has also been reported in other in vivo antimalarial studies,<sup>38,42</sup> and might be attributed to the parasite-inhibition effect of the extract preventing the destruction of RBCs by the parasite.

Secondary metabolites may be responsible for the anti-malarial activity of *D. barnimiana*. Preliminary phytochemical screening of the extract revealed the presence



of secondary metabolites like alkaloids, flavonoids, phenols, saponins, tannins, and cardiac glycosides. This phytochemical profile of the plant is similar to that of other *Dorstenia* spp., eg, *D. mannii*.<sup>51</sup>

The secondary metabolites, eg, alkaloids, found in the extract have been revealed to have antimalarial activity in other studies.<sup>52–54</sup> One of the most important antimalarial drugs, quinine, is one of the alkaloid compounds isolated from plants.<sup>53</sup> Flavonoids,<sup>54–58</sup> phenols,<sup>59,60</sup> glycosides,<sup>61</sup> and tannins<sup>60</sup> have also been reported to have antimalarial activity.

## Conclusion

The methanolic extract of *D. barnimiana* root showed moderate antimalarial activity in all models at all tested doses. The extract significantly suppressed parasitemia and increased survival time in all three model. Prevention of loss in body weight, rectal temperature, and PCV was observed at all doses on the 4-day suppressive and curative tests, and at the highest dose on the prophylactic test. These results support the traditional use of this plant for malaria treatment. However, before recommendation for use, further studies should be conducted with different models to elucidate its mechanism of action and confirm its efficacy and safety profile.

## Abbreviations

CQ25, chloroquine 25 mg/kg; OECD, Organization for Economic Cooperation and Development; PCV, packed-cell volume; RBCs, red blood cells.

## Data Sharing Statement

All data used to support the findings of this study are available from the corresponding author upon reasonable request.

## Acknowledgment

The authors want to thank Bahir Dar University for support to conduct this study.

## Author Contributions

All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data, took part in drafting the article or revising it critically for important intellectual content, agreed to submit to the current journal, gave final approval to the version to be published, and agree to be accountable for all aspects of the work.

## Funding

This research did not receive any grants from funding agencies in the public, commercial, or not-for-profit sectors.

## Disclosure

The authors report no conflicts of interest in this work.

## References

1. Malaney PIA, Spielman A, Sachs J. The malaria gap. *Am Soc Trop Med Hyg.* 2004;71(Suppl 2):141–146. doi:10.4269/ajtmh.2004.71.141
2. Russell S. The economic burden of illness for households in developing countries : a review of studies focusing on malaria, tuberculosis, and human immunodeficiency virus/acquired immunodeficiency syndrome. *Am Soc Trop Med Hyg.* 2004;71(Suppl 2):147–155. doi:10.4269/ajtmh.2004.71.147
3. World Health Organization. *World Malaria Report 2020: 20 Years of Global Progress and Challenges.* Geneva: World Health Organization; 2020.
4. Esayas E, Yared S, Massebo F, et al. Trends in malaria cases and stratification of malaria incidence in the malaria elimination setting, Harari Region, Eastern Ethiopia. *Infectious Diseases of Poverty.* 2020;9:Article 160.
5. Derebe D, Pharm B, Wubetu M, Pharm B. Antimalarial activity of hydroalcoholic root extract of *Acanthus polystachyus* Delile (Acanthaceae) against plasmodium berghei – infected Mice. *J Evid Based Integr Med.* 2019;24:1–6. doi:10.1177/2515690X19885322
6. (MCP) TCC (TCC) MCP. malaria control program review Ethiopia and Nigeria held on march 8, 2013 at the carter center, Atlanta, Georgia table of contents(MCP), T. C. C. (TCC) M. C. P. malaria control program review Ethiopia and Nigeria held on march 8, 2013 at the c. 4Th Annu Conf; 2013.
7. Aschalew Alelign TD. Current status of malaria in ethiopia : evaluation of the burden, factors for transmission and prevention methods. *Acta Parasitol Glob.* 2018;7(1):1–6.
8. Girum T, Shumbej T, Shewangizaw M. Burden of malaria in Ethiopia, 2000–2016: findings from the Global Health Estimates 2016. *Trop Dis Travel Med Vaccines.* 2019;5(1):5–11. doi:10.1186/s40794-019-0090-z
9. Wilson K, Flanagan KL, Plebanski M, Plebanski M. Malaria vaccines in the eradication era: current status and future perspectives. *Expert Rev Vaccines.* 2019;18(2):1. doi:10.1080/14760584.2019.1561289.
10. Eyasu M. Antimalarial drug resistance : in the past, current status and future perspectives. *Br J Pharmacol Toxicol.* 2015;6(1):1–15. doi:10.19026/bjpt.6.5186
11. Monjol BE, Useh MF. Detection of Plasmodium falciparum chloroquine resistance transporter (PfCRT) mutant gene amongst malaria-infected pregnant women in Calabar, Nigeria. *Ann Parasitol.* 2017;63(4):323–330. doi:10.17420/ap6304.119
12. Achan J, Talisuna AO, Erhart A, et al. Quinine, an old anti-malarial drug in a modern world : role in the treatment of malaria. *Malar J.* 2011;10(1):1–12. doi:10.1186/1475-2875-10-144
13. Yewhalaw D, Van BW, Denis L, Coosemans M, Duchateau L, Speybroeck N. First evidence of high knockdown resistance frequency in *Anopheles arabiensis* (Diptera : culicidae) from Ethiopia. *Am Soc Trop Med Hyg.* 2010;83(1):122–125. doi:10.4269/ajtmh.2010.09-0738
14. Farooq U, Mahajan RC. Drug resistance in malaria. *J Vector Borne Dis.* 2004;41(3–4):45–53.

15. Kassaye KD, Amberbir A, Getachew B, Mussema Y. A historical overview of traditional medicine practices and policy in Ethiopia. *Ethiop J Heal Dev.* 2006;20(2):127–134.
16. World Health Organization. The World Medicines Situation 2011. In: *Traditional Medicines: Global Situation Issues and Challenges.* Switzerland; 2011.
17. Noronha M, Pawar V, Prajapati A, Subramanian RB. A literature review on traditional herbal medicines for malaria. *South African J Bot.* 2020;128:292–303. doi:10.1016/j.sajb.2019.11.017
18. Karunamoorthi K, Sabesan S, Kaliyaperumal Jegajeevanram JV. Role of traditional antimalarial plants in the battle against the global malaria burden. *Vector Borne Zoonotic Dis.* 2013;13(8):521–544. doi:10.1089/vbz.2011.0946
19. Teklehaymanot T, Giday M, Medhin G, Mekonnen Y. Knowledge and use of medicinal plants by people around Debre Libanos monastery in Ethiopia. *J Ethnopharmacol.* 2007;111(2):271–283. doi:10.1016/j.jep.2006.11.019
20. Mothana RAA, Gruenert R, Bednarski PJ, Lindequist U. Evaluation of the in vitro anticancer, antimicrobial and antioxidant activities of some Yemeni plants used in folk medicine. *Pharmazie.* 2009;64.
21. Girma S, Giday M, Erko B, Mamo H. Effect of leaf extract of *Osyris quadripartita* on *Plasmodium berghei* in Swiss albino mice. *BMC Complement Altern Med.* 2015;15(1):1–9. doi:10.1186/s12906-015-0715-3
22. Teklehaymanot T, Giday M. Ethnobotanical study of medicinal plants used by people in Zegie Peninsula, Northwestern Ethiopia. *J Ethnobiol Ethnomed.* 2007;3(1):1–11. doi:10.1186/1746-4269-3-12
23. Lulekal E, Asfaw Z, Kelbessa E, Van Damme P. Ethnomedicinal study of plants used for human ailments in Ankober District, North Shewa Zone, Amhara Region, Ethiopia. *J Ethnobiol Ethnomed.* 2013;9(1):63. doi:10.1186/1746-4269-9-63
24. Birhanu Z, Endale A, Shewamene Z. An ethnomedicinal investigation of plants used by traditional healers of An ethnomedicinal investigation of plants used by traditional healers of Gondar town, North- Western Ethiopia. *J Med Plants Stud.* 2015;3(2):36–43.
25. Organization for Economic Cooperation and Development. OECD guidelines for the testing of chemicals: acute Oral Toxicity – up-and-Down-Procedure; 2008 October.
26. Council NR. *Guide for the Care and Use of Laboratory Animals.* 8th ed. National Academies Press; 2010.
27. Hoff J. *Methods of Blood Collection in the;* 2016 January.
28. Harborne JB, editor. *Phytochemical methods. A guide to modern techniques of plant analysis.* Springer science & business media; 1998.
29. Evans WC, editor. *Trease and Evans Pharmacognosy.* 15th ed. Elsevier; 2009.
30. Fidock DA, Rosenthal PJ, Croft SL, Brun R, Nwaka S. Antimalarial drug discovery: efficacy models for compound screening. *Nat Rev Drug Discov.* 2004;3(6):509520.
31. Peters W. The four-day suppressive in vivo antimalarial test. *Ann Trop Med Parasitol.* 1975;69(2):155–171. doi:10.1080/00034983.1975.11686997
32. Ryley JF, Peters W. The antimalarial activity of some quinolone esters. *Ann Trop Med Parasitol.* 1970;64(2):209–222. doi:10.1080/00034983.1970.11686683
33. Fidock DA, Rosenthal PJ, Croft SL, Brun R, Nwaka S, Einstein A. Antimalarial drug discovery: efficacy models for compound screening. *Nat Rev Drug Discov.* 2004;3(June).
34. Deressa T, Mekonnen Y, Animut A. In Vivo anti-malarial activities of *Clerodendrum myricoides*, *Dodonaea angustifolia* and *Aloe debrana* against *Plasmodium berghei*. *Ethiop J Heal Dev.* 2010;24(1):25–29.
35. Mengiste B, Makonnen E, Urga K. In vivo antimalarial activity of *dodonaea angustifolia* seed extracts against *Plasmodium Berghei* in Mice Model. *Momona Ethiopian Journal of Science.* 2012;4(1):4763.
36. David Gilmour AJS. Westergren and Wintrobe methods of estimating E.S.R. compared. *Br Med J.* 1951;2(4746):1496–1977. doi:10.1136/bmj.2.4746.1496
37. Munˆoz V, Sauvain M, Bourdy G, et al. The search for natural bioactive compounds through a multidisciplinary approach in Bolivia. Part II. Antimalarial activity of some plants used by Mosekene indians. *J Ethnopharmacol.* 2000;69(2):139–155. doi:10.1016/S0378-8741(99)00096-3
38. Mulaw T, Wubetu M, Dessie B, Demeke G, Molla Y. Evaluation of antimalarial activity of the 80 % methanolic stem bark extract of *Combretum molle* against *plasmodium berghei* in Mice. *J Evid Based Integr Med.* 2019;24:1–9. doi:10.1177/2515690X19890866
39. Toma A, Deyno S, Fikru A, Eyado A, Beale A. In vivo antiplasmodial and toxicological effect of ethanol extract of *Echinops kebericho* traditionally used in treatment of malaria in Ethiopia. *Malar J.* 2015;14(1):15–19. doi:10.1186/s12936-014-0531-0
40. Muluye AB, Melese E, Adinew GM. Antimalarial activity of 80 % methanolic extract of *Brassica nigra* (L.) Koch. (Brassicaceae) seeds against *Plasmodium berghei* infection in mice. *BMC Complement Altern Med.* 2015;15:1–8. doi:10.1186/s12906-015-0893-z
41. World Health Organization. Hazard classification-acute LD50 values of formulated products. In: *The Guidebook to the Registration of Public Health Pesticides and Repellents Against Vectors.* World Health Organization; 1975.
42. Eyasu M, Workineh Shibeshi MG. In vivo antimalarial activity of hydromethanolic leaf extract of *Calpurnia aurea* (Fabaceae) in Mice infected with chloroquine sensitive *Plasmodium berghei*. *Int J Pharmacol.* 2013;2(9):131–142.
43. Biruk H, Sentayehu B, Alebachew Y, Tamiru W, Ejigu A, Assefa S. In vivo antimalarial activity of 80 % methanol and aqueous bark extracts of *terminalia brownii* fresen. (Combretaceae) against *Plasmodium berghei* in Mice. *Biochem Res Int.* 2020;2020.
44. Atkinson CT, Dusek RJ, Woods KL, Iko WM. Pathogenicity of avian malaria in experimentally- infected Hawaii Amakihi. *J Wildl Dis.* 2000;36(2):197–204. doi:10.7589/0090-3558-36.2.197
45. Mohammed N, Abdulwuhab M, Mohammed F. Antimalarial activity of extract of *buddleja polystachya* fresen (Buddlejaceae) against *Plasmodium berghei* in Mice. *IOSR J Pharm Biol Sci.* 2016;11(5):27–35.
46. Mohammed T, Erko B, Giday M. Evaluation of antimalarial activity of leaves of *Acokanthera schimperi* and *Croton macrostachyus* against *Plasmodium berghei* in Swiss albino mice. *BMC Complement Altern Med.* 2014;14(314):1–10. doi:10.1186/1472-6882-14-314
47. Nureye D, Assefa S, Nedi T, Engidawork E. In vivo antimalarial activity of the 80% methanolic root bark extract and solvent fractions of *Gardenia ternifolia* Schumach. & Thonn. (Rubiaceae) against *Plasmodium berghei*. *Evid Based Complement Altern Med.* 2018;2018:1–10. doi:10.1155/2018/9217835
48. Balogun EA, Akinloye OA, Lasisi AA, Adeyi OE. Biochemical and histological changes associated with treatment of malaria and diabetes mellitus in mice with extracts of *Mormodica charantia*. *An Int J Niger Soc Exp Biol.* 2012;24(1):38–47.
49. Iyawe HOTA, Onigbinde AO. Effects of *plasmodium berghei* infection and folic acid treatment on biochemical and antioxidant indicators in Mice. *Nat Sci.* 2010;8(04):2–5.
50. Lamikanra AA, Brown D, Potocnik A, Casals-pascual C, Langhorne J, Roberts DJ. Malarial anemia: of mice and men. *Blood.* 110(1):18–29.

51. Agem KF, Teke GN, Bathelemy N, Charles F, Jean-paul D, Lucien KH. In vitro antifungal activity of *Dorstenia mannii* leaf extracts (Moraceae). *African J Biotechnol.* 2015;14(46):3164–3169.
52. Federal U, Gerais DM. Plant-derived antimalarial agents : new leads and efficient phytochemicals. Part I. Alkaloids. *An Acad Bras Cienc.* 2009;81(4):715–740. doi:10.1590/S0001-37652009000400011
53. Saxena S, Dej NP. Antimalarial agents from plant sources. *Curr Sci.* 1314–1329.
54. Kaur K, Jain M, Kaur T, Jain R. Antimalarials from nature. *Bioorg Med Chem.* 2009;17(9):3229–3256. doi:10.1016/j.bmc.2009.02.050.
55. Batista R, De JA, Júnior S, De OAB. Plant-derived antimalarial agents: new leads and efficient phytochemicals. Part II. Non-Alkaloidal Natural Products. 2009;14(8):3037–3072.
56. Oliveira FQ, Andrade-neto V, Krettli AU, Brandão MGL. New evidences of antimalarial activity of *Bidens pilosa* roots extract correlated with polyacetylene and flavonoids. *Journal of Ethnopharmacology.* 2004;93(1):39–42. doi:10.1016/j.jep.2004.03.026
57. Lim SS, Kim H, Lee D. Antimalarial activity of flavonoids and chalcones. *Bull Chem Soc.* 2007;28(12):2495–2497.
58. Di Carlo G, Mascolo N, Izzo AA, Capasso F. Flavonoids: old and new aspects of a class of natural therapeutic drugs. *Life Sciences.* 1999;65:337–353.
59. Tjahjandarie TS, Pudjiastuti P, Saputri RD, Tanjung M. Antimalarial and antioxidant activity of phenolic compounds isolated from *Erythrina crista-galli* L. *J Chem Pharm Res.* 2014;6(4):786–790.
60. Bero J, Fre M, Quetin-Leclercq J. Antimalarial compounds isolated from plants used in traditional medicine. *J Pharm Pharmacol.* 2009;61(11):1401–1433. doi:10.1211/jpp.61.11.0001
61. Libmana A, Zhanga H, Maa C, et al. A first new antimalarial pregnane glycoside from *Gongronema napalense*. *Asian J Tradit Med.* 2008;3(6):203–210.

### Clinical Pharmacology: Advances and Applications

Dovepress

### Publish your work in this journal

Clinical Pharmacology: Advances and Applications is an international, peer-reviewed, open access journal publishing original research, reports, reviews and commentaries on all areas of drug experience in humans. The manuscript management system is completely online and

includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/clinical-pharmacology-advances-and-applications-journal>